http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
LYRICA® (pregabalin) Phase 3 Trial in Pediatric Epilepsy Meets Primary Endpoint
-
IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery
-
IBM and Pfizer to Accelerate Immuno-oncology Research with Watson for Drug Discovery
-
Pfizer (PFE) Announces REFLECTIONS B3271002 Study Met Primary Endpoint
-
Pfizer Announces Positive Top-Line Results from the Pivotal Comparative REFLECTIONS B3271002 Study for PF-05280014, a Potential Biosimilar to Herceptin®1 (trastuzumab)
-
FDA Accepts BLA for Avelumab for Treatment of MCC for Priority Review (PFE)
-
FDA Accepts the Biologics License Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma for Priority Review
-
Anthony J. Maddaluna, Executive Vice President and President of Pfizer Global Supply to Retire
-
Pfizer (PFE) Announces Publication of Positive Phase 3 PALOMA-2 Data; Strong PFS Results Noted
-
PALOMA-2 Phase 3 Study Published In The New England Journal Of Medicine Demonstrates Clinical Benefit Of Pfizer’s IBRANCE® (palbociclib) In First-Line ER+, HER2- Metastatic Breast Cancer
-
Pfizer Announces Results from Phase 3 OPAL Clinical Development Program Investigating XELJANZ® (Tofacitinib Citrate) for Psoriatic Arthritis
-
Eton Park Capital's 13F Shows New Stakes Twitter (TWTR), Kinder Morgan (KMI), Whitewave (WWAV), Increase in Microsoft (MSFT) (More...)
-
Pfizer to Collaborate with National Cancer Institute to Study Three Immunotherapy Agents Targeting Multiple Cancers
-
Pfizer (PFE) Announces Strong Data from PRECISION Trial in OA, RA Patients
-
Landmark Study Demonstrates Pfizer’s Celebrex (Celecoxib)Has Similar Cardiovascular Risk As Compared To Prescription Doses Of Ibuprofen and Naproxen
-
Pfizer (PFE) to Expand HAP; Includes Broader Access to Prevenar 13
-
Pfizer Announces Major Expansion of Humanitarian Assistance Program
-
Bristol-Myers Squibb and Pfizer to Deliver 12 New Eliquis® (apixaban) Presentations at American Heart Association (AHA) Scientific Sessions 2016
-
Pfizer's (PFE) IBRANCE Receives European Approval as HR+/HER2- Metastatic Breast Cancer Treatment
-
IBRANCE® (palbociclib) Receives Approval in European Union for the Treatment of Women with HR+/HER2- Metastatic Breast Cancer
-
Pfizer (PFE) Announces Presentation of Additional XELJANZ Data at 2016 ACR/ARHP Annual Meeting
-
Pfizer to Present Additional Research For XELJANZ® (Tofacitinib Citrate) In Rheumatologic Diseases, Including Rheumatoid Arthritis and Psoriatic Arthritis
-
Spark Therapeutics (ONCE), Pfizer (PFE) Announce Presentation of Updated SPK-9001 Phase 1/2 data in Hemophilia B
-
Spark Therapeutics and Pfizer Announce Updated Data from Hemophilia B Phase 1/2 Trial Suggesting Sustained Therapeutic Levels of Factor IX Activity
-
Pfizer (PFE) Receives CFDA Approval of Prevenar 13 for Invasive Diseases
-
Pfizer’s Prevenar 13® Receives Approval For Use in Infants and Children in China
-
Pfizer (PFE) to Discontinue Bococizumab Development Program; Sees EPS Impact
-
Pfizer Discontinues Global Development of Bococizumab, Its Investigational PCSK9 Inhibitor
-
European Medicines Agency Validates the Marketing Authorization Application for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
-
Debiopharm International SA Announces Clinical Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer in Cancer Immunotherapy
-
CDC Advisory Committee on Immunization Practices Votes to Recommend New Dosing Schedule for Vaccination with TRUMENBA® (Meningococcal Group B Vaccine)
-
Pfizer (PFE) Receives Award to Conduct GBS Vaccine Phase 1/2
-
Pfizer Awarded Grant to Evaluate Vaccine to Protect Newborns Against Group B Streptococcus Infection
-
Pfizer Awarded Grant to Evaluate Vaccine to Protect Newborns Against Group B Streptococcus Infection
-
Pfizer (PFE) Says INFLECTRA Biosimilar Now Available in U.S.
-
Pfizer Announces The U.S. Availability Of Biosimilar INFLECTRA® (infliximab-dyyb)
-
Pfizer to Present New Data on XELJANZ® (Tofacitinib Citrate) for Ulcerative Colitis at UEG Week 2016
-
Pfizer (PFE) Announces Strong Data from SUTENT Phase 3 in RCC; DFS Extension Noted
-
Pfizer (PFE) Presents Encouraging New Data for INLYTA Combo Phase 1b in Adv. RCC
-
First Positive Phase 3 Results in Adjuvant Setting for Renal Cell Carcinoma Show SUTENT® (sunitinib) Extended Disease Free Survival After Surgical Removal
-
Pfizer Presents Promising New Immunotherapy Combination Data With INLYTA® (axitinib) In Advanced Renal Cell Carcinoma (RCC)
-
Notable Mergers and Acquisitions 10/6: (ICUI)/(PFE) (KLAC)/(LRCX) (TWTR)/(GOOG) (WCG)
-
Pre-Open Stock Movers 10/06: (ALQA) (SCYX) (ZUMZ) Higher; (ALNY) (TWTR) (MDCO) Lower (more...)
-
ICU Medical (ICUI) to Acquire Pfizer's (PFE) Hospira Infusion Systems Business in $1B Deal
-
ICU Medical Inc. to Acquire the Hospira Infusion Systems Business from Pfizer Inc. for $1 Billion in Cash and Stock
-
Top 10 News for 9/26 - 9/30: Deutsche Bank Soars on Settlement; Twitter Back in the M&A Fray; Nike 'Just Didn't Do It' in Q1
-
Pfizer (PFE) Closes Medivation (MDVN) Acquisition
-
Pfizer Completes Acquisition of Medivation
-
Pfizer to Showcase Progress of Broad-Based Oncology Portfolio at European Society for Medical Oncology (ESMO) 2016 Congress
-
Pfizer (PFE) Says HSR Act Waiting Period in Medivation (MDVN) Acquisition has Expired

